Characterization of the Kynurenine Pathway in Human Neurons
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The kynurenine pathway is a major route of l-tryptophan catabolism producing neuroactive metabolites implicated in neurodegeneration and immune tolerance. We characterized the kynurenine pathway in human neurons and the human SK-N-SH neuroblastoma cell line and found that the kynurenine pathway enzymes were variably expressed. Picolinic carboxylase was expressed only in primary and some adult neurons but not in SK-N-SH cells. Because of this difference, SK-N-SH cells were able to produce the excitotoxin quinolinic acid, whereas human neurons produced the neuroprotectant picolinic acid. The net result of kynurenine pathway induction in human neurons is therefore predicted to result in neuroprotection, immune regulation, and tumor inhibition, whereas in SK-N-SH cells, it may result in neurotoxicity, immune tolerance, and tumor promotion. This study represents the first comprehensive characterization of the kynurenine pathway in neurons and the first description of the involvement of the kynurenine pathway as a mechanism for controlling both tumor cell neurotoxicity and persistence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“Uyttenhove et al. (2003) showed that a majority of human tumors constitutively express IDO.”
BackgroundQuinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · cited 1×
“Recent studies suggest IDO as a target for cancer suppression in vivo (Munn and Mellor, 2004, 2007; Muller et al., 2005; Zamanakou et al., 2007).”
BackgroundNeuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948
Hilmas, C., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R., & Albuquerque, E. X. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 859
Tryptophan and the immune response
Moffett, J. R., & Namboodiri, M. A. (2003) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.2003.t01-1-01177.x · Cited by 760
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 538
Self-citationGuillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497 · cited 7×
“Purity of primary cultures of human fetal neurons Consistent with our previous data (Guillemin et al., 2005b), after 7 d in culture, 90 –95% of the fetal brain cells immunostained for the neuronal marker MAP2 (data not shown).”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 4
- Curatolo, 1996, Modulation of extracellular kynurenic acid content by excitatory amino acids in primary cultures of rat astrocytes, Adv Exp Med Biol, 398, 273, 10.1007/978-1-4613-0381-7_43 · doi:10.1007/978-1-4613-0381-7_43
- Kerr, 1997, Kynurenine pathway inhibition with 6-chloro-D-tryptophan reduces neurotoxicity of HIV-infected macrophage supernatants (Abstract), Neurology, 48, A94
- Kovalenko, 1989, [The effect of picolinic acid and iron ions on the proliferation of SPEV cells.], Tsitologiia, 31, 447
- 10.1007/s10571-005-8469-y · DOI
Cited by
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Neuroinflammation and depression: A review
Troubat, R., Barone, P., Leman, S., Desmidt, T., Cressant, A., Atanasova, B., Brizard, B., El Hage, W., Surget, A., Belzung, C., et al. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14720 · Cited by 1,107
Inflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628
Self-citationQuinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Self-citationThe kynurenine pathway and the brain: Challenges, controversies and promises
Schwarcz, R., & Stone, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.003 · Cited by 461
Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule
Yabut, J. M., Crane, J. D., Green, A. E., Keating, D. J., Khan, W. I., & Steinberg, G. R. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00283 · Cited by 411
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Self-citationQuinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394
“As shown previously in cortical neurons, dopaminergic neurons do not produce QUIN but take it up from the microenvironment [15, 40].”
BackgroundInterleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388
Wirthgen, E., Hoeflich, A., Rebl, A., & Günther, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01957 · Cited by 378
Won, E., & Kim, Y.-K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113006 · Cited by 300
“The results of these studies demonstrated that induction of IDO is a common feature of interferon-gamma action, and the extent of this induction is influenced by extracellular Ltryptophan concentrations, and IDO is the only enzyme in the formation of 3-hydroxyanthranilic acid from tryptophan which…”
BackgroundInflammation and the two-hit hypothesis of schizophrenia
Feigenson, K. A., Kusnecov, A. W., & Silverstein, S. M. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.006 · Cited by 282
Favennec, M., Hennart, B., Caiazzo, R., Leloire, A., Yengo, L., Verbanck, M., Arredouani, A., Marre, M., Pigeyre, M., Bessede, A., et al. (2015) · Obesity · doi:10.1002/oby.21199 · Cited by 276
Self-citationStein, L. R., & Imai, S. (2014) · The EMBO Journal · doi:10.1002/embj.201386917 · Cited by 265
“Moreover, there are multiple precursors for and pathways of NAD+ biosynthesis, all of which are expressed in the hippocampus (Guillemin et al, 2007).”
BackgroundThe Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257
Self-citationImpaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Fernandes, B. S., Steiner, J., Molendijk, M. L., Dodd, S., Nardin, P., Gonçalves, C.-A., Jacka, F., Köhler, C. A., Karmakar, C., Carvalho, A. F., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30370-4 · Cited by 247
Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons
Braidy, N., Grant, R., Adams, S., Brew, B. J., & Guillemin, G. J. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9051-z · Cited by 226
“Neurons were prepared from the same mixed brain cell cultures as previously described (Guillemin et al. 2007).”
MethodInfluentialSelf-citationMithaiwala, M. N., Santana-Coelho, D., Porter, G. A., & O’Connor, J. C. (2021) · Cells · doi:10.3390/cells10061548 · Cited by 190
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Kynurenine pathway metabolites and suicidality
Bryleva, E. Y., & Brundin, L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.034 · Cited by 168
“Primary neuronal cultures isolated from fetal human brains were also found to constitutively produce PIC (Guillemin et al., 2007).”
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
“…et al., 2003b), we showed that it is only partly present (i.e., that some specific enzymes of the pathway are not expressed) in human astrocytes (Guillemin et al., 2001a), neurons (Guillemin et al., 2007b), oligodendrocyte (Lim et al., 2007) and endothelial cells (Owe-Young et al., 2008).”
BackgroundInfluentialSelf-citationOades, R. D., Dauvermann, M. R., Schimmelmann, B. G., Schwarz, M. J., & Myint, A.-M. (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-29 · Cited by 151
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141
“It is of significance as QUIN is a potent excitotoxin, whereas PIC is a neuroprotectant ( Guillemin et al. 2007 ).”
BackgroundSelf-citationHuang, Y., Zhao, M., Chen, X., Zhang, R., Le, A., Hong, M., Zhang, Y., Jia, L., Zang, W., Jiang, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0916 · Cited by 138
“KMO is expressed in resident macrophages in adipose tissue [39] and predominantly in microglia [40] but not in neurons or astrocytes in the brain [41, 42] In TBI or neurodegenerative conditions, the main ratelimiting enzyme in neurotoxicity, KMO, is activated by proinflammatory factors in microglia to generate neuroto…”
BackgroundPeripheral and central kynurenine pathway abnormalities in major depression
Paul, E. R., Schwieler, L., Erhardt, S., Boda, S., Trepci, A., Kämpe, R., Asratian, A., Holm, L., Yngve, A., Dantzer, R., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.01.002 · Cited by 134
Effects of inflammation on the kynurenine pathway in schizophrenia—a systematic review
Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., & Mulert, C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1721-z · Cited by 119
Neuropsychiatric disorders related to interferon and interleukins treatment
Myint, A. M., Schwarz, M. J., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9114-5 · Cited by 116
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Whiteman, I. T., Gervasio, O. L., Cullen, K. M., Guillemin, G. J., Jeong, E. V., Witting, P. K., Antao, S. T., Minamide, L. S., Bamburg, J. R., & Goldsbury, C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3531-09.2009 · Cited by 92
“Primary human neurons were prepared and cultured for 14 –20 d as previously described (Guillemin et al., 2007).”
MethodSelf-citationBraidy, N., Gai, W.-P., Xu, Y. H., Sachdev, P., Guillemin, G. J., Jiang, X.-M., Ballard, J. W. O., Horan, M. P., Fang, Z. M., Chong, B. H., et al. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-20 · Cited by 91
“Human foetal cortical neurons were prepared from mixed brain cell cultures as previously described [14].”
MethodSelf-citationZavitsanou, K., Lim, C. K., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S. D., Guillemin, G. J., & Weickert, C. S. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.05.011 · Cited by 46
Self-citationKorkmaz, Ş. A., Kızgın, S., Oğuz, E. F., Neşelioğlu, S., & Erel, Ö. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.07.079 · Cited by 24
Metadata
- Authors
- Guillemin, G. J., Cullen, K. M., Lim, C. K., Smythe, G. A., Garner, B., Kapoor, V., Takikawa, O., & Brew, B. J.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2007-11-21
- Volume
- 27
- Issue
- 47
- Pages
- 12884-12892
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2053806684
- Cited by
- 324
- References
- 64
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.